COGT
Cogent Biosciences, Inc. Common StockstockNASDAQ
unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual's cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum's approach is not restricted by antigens and may have applications for treating many types of cancers. unum's vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 29.14 | 2026-11-12 | -4.80% | 1.578 |
| 1M | 30.01 | 2026-10-19 | -7.56% | 1.402 |
| 3M | 36.85 | 2026-08-19 | -24.72% | 1.379 |
| 6M | 31.25 | 2026-05-19 | -11.23% | 1.405 |
| 1Y | 34.94 | 2025-11-19 | -20.61% | 1.378 |
| 2Y | 9.06 | 2024-11-19 | +206.18% | — |
| 5Y | 9.80 | 2021-11-19 | +183.06% | 1.224 |
Cogent Biosciences, Inc. Common Stock (NASDAQ:COGT) stock price today is $27.74, and today's volume is 1,350,367. COGT is down 0.252% today. The 30 day average volume is 2.29M. COGT market cap is $4.83B with 173.99M shares outstanding.
